drugset / Trial / NCT00192335
Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants
RandomizedSingle-groupDouble-blindTreatment
Summary
* Primary objective is to demonstrate equivalent immunogeniticity of CAIV-T and FluMist * Secondary objective of this study is to assess the safety and tolerability of CAIV-T compared to FluMist
Timeline
- Start
- 2004-07
- Primary completion
- —
- Completion
- 2005-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | FluMist | Vaccine | 0.2 ml | Intranasal |
| Comparator | FluMist | Vaccine | 0.5 ml | Intranasal |
Indications
No indication recorded.